Viridian Therapeutics Announced Phase 1 Results For VRDN-008; Demonstrated Deep And Sustained IGG Reduction Through 8 Weeks After Subcutaneous Dosing, With 74% Reduction At Peak

Benzinga
Open on Benzinga